Pierre de Flon1, Katarina Laurell2, Lars Söderström3, Martin Gunnarsson4, Anders Svenningsson5. 1. Department of Neurology, Östersund Hospital, Östersund, Sweden/Neurology Unit, Department of Pharmacology and Clinical Neuroscience, Umeå University, Östersund, Sweden. 2. Neurology Unit, Department of Pharmacology and Clinical Neuroscience, Umeå University, Östersund, Sweden. 3. Unit of Research, Education and Development, Östersund Hospital, Region Jämtland Härjedalen, Östersund, Sweden. 4. Department of Neurology, School of Medical Sciences, Örebro University, Örebro, Sweden. 5. Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden/Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Abstract
OBJECTIVE: New disease-modifying treatment strategies in multiple sclerosis offer possibilities for individualised treatment. In this study, we evaluated patient-reported outcome measures before and after a switch in therapy from first-line injectable treatments to rituximab. METHOD: A total of 75 patients with clinically stable relapsing-remitting multiple sclerosis (RRMS) receiving ongoing first-line injectable treatment at three Swedish centres had their treatment switched to rituximab in this open-label phase II multicentre study. Assessment of treatment satisfaction, patient-perceived impact of the disease on daily life, fatigue, cognitive symptoms and disease progression was performed 3 months before and at the time of the treatment shift and then for a subsequent 2-year period. RESULTS: The overall treatment satisfaction rating improved significantly from a mean of 4.8 (scale range: 1-7), while on injectable therapies, to a mean of 6.3 after 1 year of rituximab treatment ( p < 0.001). This improvement was sustained after 2 years. There was no significant change in scores for patient-perceived impact of disease, fatigue or disease progression. CONCLUSION: A shift in therapy from first-line injectables to rituximab in a cohort of clinically stable RRMS patients was followed by improved treatment satisfaction. This is clinically relevant as it may influence long-term adherence to immunomodulating therapy.
OBJECTIVE: New disease-modifying treatment strategies in multiple sclerosis offer possibilities for individualised treatment. In this study, we evaluated patient-reported outcome measures before and after a switch in therapy from first-line injectable treatments to rituximab. METHOD: A total of 75 patients with clinically stable relapsing-remitting multiple sclerosis (RRMS) receiving ongoing first-line injectable treatment at three Swedish centres had their treatment switched to rituximab in this open-label phase II multicentre study. Assessment of treatment satisfaction, patient-perceived impact of the disease on daily life, fatigue, cognitive symptoms and disease progression was performed 3 months before and at the time of the treatment shift and then for a subsequent 2-year period. RESULTS: The overall treatment satisfaction rating improved significantly from a mean of 4.8 (scale range: 1-7), while on injectable therapies, to a mean of 6.3 after 1 year of rituximab treatment ( p < 0.001). This improvement was sustained after 2 years. There was no significant change in scores for patient-perceived impact of disease, fatigue or disease progression. CONCLUSION: A shift in therapy from first-line injectables to rituximab in a cohort of clinically stable RRMS patients was followed by improved treatment satisfaction. This is clinically relevant as it may influence long-term adherence to immunomodulating therapy.
Authors: Irene Eriksson; Thomas Cars; Fredrik Piehl; Rickard E Malmström; Björn Wettermark; Mia von Euler Journal: Eur J Clin Pharmacol Date: 2017-11-11 Impact factor: 2.953
Authors: Rodolfo A Kölliker Frers; Matilde Otero-Losada; Tamara Kobiec; Lucas D Udovin; María Laura Aon Bertolino; María I Herrera; Francisco Capani Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786
Authors: Brandi L Vollmer; Kavita Nair; Stefan Sillau; John R Corboy; Timothy Vollmer; Enrique Alvarez Journal: Ann Clin Transl Neurol Date: 2020-08-06 Impact factor: 4.511